about
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSSeven prostate cancer susceptibility loci identified by a multi-stage genome-wide association studyIdentification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.miRNAs associated with prostate cancer risk and progressionCutaneous beta human papillomaviruses and the development of male external genital lesions: A case-control study nested within the HIM Study.Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer.Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study.Human papillomavirus virus (HPV) genotype- and age-specific analyses of external genital lesions among men in the HPV Infection in Men (HIM) StudySmoking relapse-prevention intervention for cancer patients: Study design and baseline data from the surviving SmokeFree randomized controlled trialStrategies for power calculations in predictive biomarker studies in survival dataA Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaCoexpression and expression quantitative trait loci analyses of the angiogenesis gene-gene interaction network in prostate cancer.Natural history of cutaneous human papillomavirus (HPV) infection in men: the HIM study.Role of nicotine dependence on the relationship between variants in the nicotinic receptor genes and risk of lung adenocarcinomaCHRNA5 variants moderate the effect of nicotine deprivation on a neural index of cognitive controlChemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.Natural history of polyomaviruses in men: the HPV infection in men (HIM) study.SNP-SNP interaction network in angiogenesis genes associated with prostate cancer aggressivenessUnderutilization of the AIDS Drug Assistance Program: associated factors and policy implications.LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer.Male circumcision and the incidence and clearance of genital human papillomavirus (HPV) infection in men: the HPV Infection in men (HIM) cohort study.MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium.Long-term persistence of oral human papillomavirus type 16: the HPV Infection in Men (HIM) study.A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate CancerThe role of toxicity-related regimen changes in the development of antiretroviral resistanceIdentification of six new susceptibility loci for invasive epithelial ovarian cancer.Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) RiskCourse and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison.Race and prevalence of human papillomavirus infection among men residing in Brazil, Mexico and the United States.Genital human papillomavirus (HPV) concordance in heterosexual couples.A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) RiskHeat shock proteins HSP27 and HSP70 are present in the skin and are important mediators of allergic contact hypersensitivityAtlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulationIncidence, Duration, Persistence, and Factors Associated With High-risk Anal Human Papillomavirus Persistence Among HIV-negative Men Who Have Sex With Men: A Multinational StudyUncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic.
P50
Q28584533-A1F5EF5E-5A51-4B1F-902C-F5C3F28E0CBDQ29417074-A01CD539-D462-4228-83DF-059CE1FA9A7BQ29417155-900DD576-5605-420D-A9C4-BE0E86BF14C0Q30235186-96F39FD8-C172-4585-80E7-2C6C31D69C9FQ30276138-98BC07F8-37BE-4542-819E-66D19E4A3A20Q30277784-3828FA08-1123-49CF-9FA7-54B266A09996Q30278587-CC7EEEFE-06A6-4F84-BB7B-65DD75A24998Q30279220-E8316210-5998-4811-AEF8-4BC871ABD1ABQ30303055-2D8120C7-113E-42DD-BD4A-22846274845AQ31118116-87B3F289-0D33-4EA3-9931-118064CE4FFEQ31132692-B7ACB66F-9F72-4076-9EF7-AEA6FDFF0049Q33426534-761AC183-2E19-4FA3-9B36-5FE2845C1F2AQ33838280-21EE3A63-B824-4CA7-A9F4-C37FD83196D6Q34149686-E8E8BD83-188C-4B36-B7F1-B9B5503F6E2AQ34214951-FCCE5850-6BB8-436D-B44E-FE13B4012C5AQ34262638-F0D51165-6C6E-490E-86D7-9D160AE2A66EQ34406418-CF2B9A47-64A2-413E-A1C5-75DBB2ACE637Q34447373-867DE6BD-E687-4A5F-9211-C1C6A22E2DFEQ34672464-61CCD2B9-4AFD-44F3-8EB7-6AB7A3E9FB15Q34990815-08412983-DD5A-4476-8B97-E471AA55BEF7Q35022313-378F91C5-455D-4601-BCB7-A0CD094A03C6Q35091981-9BC3D48B-4158-4F99-A2C0-6F6295D90D6DQ35156802-3A870217-3D05-4C8B-99CD-2F1332D0455CQ35163993-DFD13A61-400B-43F5-B0B8-A95711A418C2Q35248192-9F70FA32-A8DB-4167-9B5F-EFE35A54341DQ35327105-1CB7619C-E234-454A-88A1-2C70B7B037CBQ35330053-701BFC0E-7DB4-43D6-9BD4-449785E76A50Q35541663-195153C6-89E8-4BDE-AFF8-77C01086CE2CQ35646703-54AD61FF-9DE7-4E1B-907E-B9FE1DFEB6C4Q35668946-6E873FCB-180D-43A8-B63B-A2A02AC26F09Q35708734-345D6F47-52BD-44E1-8DBE-4FAE679653A8Q35987488-0DDFC7D1-E2B0-42E1-AFD0-789F947105AAQ36280182-7DDF3A65-ED18-41A7-81CF-509B47BD53DFQ36376205-4853F6C3-E428-4EC2-A014-2C79DBF76E5FQ36477652-02D1576D-C42B-4FDF-8766-714125EACAA8Q36487146-E136363D-DE26-4484-AFAA-4FBDC6564763Q36613524-A226A341-FD2C-4A49-8178-F2AF87E753E0Q36792641-44C21E36-90A4-4492-8F33-E4A89D5F1E4CQ36915102-C8FFF796-59CF-4492-9F7F-EE086091C4D5Q36967041-C51A5CF9-4EC9-4AF5-9083-B022E234B0AE
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hui-Yi Lin
@ast
Hui-Yi Lin
@en
Hui-Yi Lin
@es
Hui-Yi Lin
@nl
Hui-Yi Lin
@sl
type
label
Hui-Yi Lin
@ast
Hui-Yi Lin
@en
Hui-Yi Lin
@es
Hui-Yi Lin
@nl
Hui-Yi Lin
@sl
prefLabel
Hui-Yi Lin
@ast
Hui-Yi Lin
@en
Hui-Yi Lin
@es
Hui-Yi Lin
@nl
Hui-Yi Lin
@sl
P106
P1153
56637279300
P214
4558149489157293810007
P2798
P31
P496
0000-0002-3307-5549
P7859
viaf-4558149489157293810007